Prostate cancer: making the switch from LHRH antagonist to LHRH agonist.
Publication
, Other
Moul, JW
Published in: Nat Rev Urol
January 31, 2012
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Nat Rev Urol
DOI
EISSN
1759-4820
Publication Date
January 31, 2012
Volume
9
Issue
3
Start / End Page
125 / 126
Location
England
Related Subject Headings
- Urology & Nephrology
- Prostatic Neoplasms
- Oligopeptides
- Male
- Humans
- Hormone Antagonists
- Gonadotropin-Releasing Hormone
- Clinical Trials as Topic
- 3202 Clinical sciences
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Moul, J. W. (2012). Prostate cancer: making the switch from LHRH antagonist to LHRH agonist. Nat Rev Urol. England. https://doi.org/10.1038/nrurol.2012.5
Moul, Judd W. “Prostate cancer: making the switch from LHRH antagonist to LHRH agonist.” Nat Rev Urol, January 31, 2012. https://doi.org/10.1038/nrurol.2012.5.
Moul JW. Prostate cancer: making the switch from LHRH antagonist to LHRH agonist. Vol. 9, Nat Rev Urol. 2012. p. 125–6.
Moul, Judd W. “Prostate cancer: making the switch from LHRH antagonist to LHRH agonist.” Nat Rev Urol, vol. 9, no. 3, 31 Jan. 2012, pp. 125–26. Pubmed, doi:10.1038/nrurol.2012.5.
Moul JW. Prostate cancer: making the switch from LHRH antagonist to LHRH agonist. Nat Rev Urol. 2012. p. 125–126.
Published In
Nat Rev Urol
DOI
EISSN
1759-4820
Publication Date
January 31, 2012
Volume
9
Issue
3
Start / End Page
125 / 126
Location
England
Related Subject Headings
- Urology & Nephrology
- Prostatic Neoplasms
- Oligopeptides
- Male
- Humans
- Hormone Antagonists
- Gonadotropin-Releasing Hormone
- Clinical Trials as Topic
- 3202 Clinical sciences
- 1103 Clinical Sciences